reference/33569969

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33569969

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, N.I.H., Extramural
endingPage	379
issn	1573-0646 0167-6997
issueIdentifier	4
pageRange	369-379
publicationName	Investigational New Drugs
startingPage	369
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4 http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_28e785964ae49a747ebf9fd72022ff2d http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_01a74961205fd42863434f526764c2b4 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_150e1718129472efbb16b594884e4a53 http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c7ef8ab3e04806e55ba8d929f8469018
bibliographicCitation	Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Investigational New Drugs. 2008 Feb 16;26(4):369–79. doi: 10.1007/s10637-008-9123-6.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_342023202d84de6cdb86347b351d8465 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_038637ff79376d434ea1a463720dfe68 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4dd663cd1233797d6fd3dea78ace898c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_87d792c8febbe7ec377742c73a9f8a7e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e57cd43a2726b94165062ec9bb063d24 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f1ab87603bcb819aff5faf79d4cf72f9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e31d06c9ae90607ece0723228202c953 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c59fad56ee8fb6acdc68ecc548c25af http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2e14ad1a27c57de025e40bba78e2160 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dc5dd01eaeec0b5176e2fd9a1d142e4e
date	2008-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/PMC4461052 https://pubmed.ncbi.nlm.nih.gov/18278438 https://doi.org/10.1007/s10637-008-9123-6
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4372 https://portal.issn.org/resource/ISSN/0167-6997 https://portal.issn.org/resource/ISSN/1573-0646
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
discusses	http://id.nlm.nih.gov/mesh/M0005997 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0021379 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0018233 http://id.nlm.nih.gov/mesh/M0247080 http://id.nlm.nih.gov/mesh/M0209583 http://id.nlm.nih.gov/mesh/M0019072
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10820 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8766 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8321 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_1.17.4.2 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9571836 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6795 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127559277 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129712026 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID6241 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764

Total number of triples: 60.